Should I charge per unit or per area for neuromodulators, and how do the two models compare?

Charge per unit when your patient mix skews toward light and moderate dosing and you want a price a patient can verify against her chart. Charge per area when you treat a lot of heavy dosers, when you want a quotable number at the front desk, and when you are confident in your own dosing discipline. Most clinics that get this right are not purists. They run per unit on the upper face and per area on the specific indications where dose varies so wildly that a per unit quote stops being useful.

The reason the question keeps coming back is that the two models fail in opposite directions. Per unit pricing is honest and it scales with product cost, but it invites shopping on a single number that says nothing about who is holding the syringe. Per area pricing reads as a package and protects you when a masseter case eats 50 units a side, but it silently transfers margin away from you the moment your average dose creeps up.

What follows is the arithmetic, the indications where each model breaks, and a way to change models without setting fire to your existing book.

How each model bills, in plain terms

Per unit means the patient pays a posted rate multiplied by the units actually drawn and injected. A glabella at 20 units of onabotulinumtoxinA at $13 per unit is $260. If you dose that same glabella at 24 units because she is a strong corrugator, she pays $312. The chart and the invoice agree, line for line.

Per area means the patient pays a flat fee for a named treatment zone regardless of dose. Glabella, forehead, crow's feet, each a fixed price. Your $325 glabella is $325 whether you used 18 units or 26.

Two practical notes before the math. First, units are not interchangeable across products. AbobotulinumtoxinA is dosed in its own units and requires roughly two and a half to three of them to approximate one unit of onabotulinumtoxinA, so a per unit price list that does not name the product is meaningless. Second, per area pricing forces you to define the area in writing. If "forehead" in your price list quietly includes the glabella for some injectors and not others, you have created a refund conversation you will lose.

Keep reading: How do I take before and after photos that will hold up as clinical evidence later?

Cost of goods per unit across common neuromodulators

Your cost per unit is vial acquisition cost divided by usable units, not by label units. Reconstitution waste, the dead space in the hub, and any product you discard at the end of a session all belong in the denominator.

Work it in front of yourself. Assume, and these are your numbers to replace, that a 100 unit vial lands at $560 after your current buying tier and any invoice terms. Assume you reliably draw 96 usable units from it because of hub loss and the last partial draw. Your cost is $5.83 per usable unit. Now assume you discard, on average, six units per vial across a month because of single patient days and short sessions. Effective usable units drop to 90 and your true cost is $6.22.

That gap between $5.83 and $6.22 is not rounding. On 4,000 units a month it is $1,560. Larger vial sizes lower the per unit cost only if you actually use them inside the reconstituted window your protocol allows. A 200 unit vial you half discard is more expensive per treated unit than a 50 unit vial you finish.

• Track usable units, not label units. Log units drawn and units discarded on the treatment record, tied to the lot.
• Recalculate cost per unit quarterly. Buying tiers, rebates and vial mix all move.
• Price off the higher figure. If your waste adjusted cost is $6.22, price against $6.22.

Which model protects margin on masseter and platysma work

This is where per area pricing quietly bleeds. Upper face dosing sits in a fairly narrow band. Masseter and platysmal band work does not. A conservative masseter reduction might run 20 to 25 units per side. A strong bruxer with a well developed muscle can take considerably more, and a platysmal treatment across multiple bands is a large dose by any standard.

Put numbers on it at a waste adjusted cost of $6.22 per unit. A flat masseter price of $600 against 40 total units carries $249 of product cost and leaves $351 before chair time and overhead. The same $600 against 100 total units carries $622 of product cost. You are underwater before you have paid for the room.

The clean answer for these indications is per unit, or per area with a stated unit ceiling and a posted overage rate. Something like: masseter package covers up to 50 total units, additional units at your standard per unit rate. That is defensible, it is easy to say out loud, and it stops the heaviest cases from subsidizing themselves out of your margin.

Keep reading: What actually happens in the two weeks after a filler treatment, and when is a touch up appropriate?

Patient perception, price shopping and quoted totals

Patients do not compare injectors. They compare numbers they can find. A per unit price is findable and therefore comparable, which is why per unit clinics end up defending a rate against a med spa two towns over that is running an introductory offer on a product it will not name.

Per area pricing sidesteps that comparison by changing the unit of account. The patient asks what a forehead costs and hears one number. The tradeoff is suspicion. Experienced patients who have been treated per unit elsewhere will ask how many units they are getting, and if the answer is vague they will assume you are underdosing to protect the flat fee.

You can have it both ways. Quote per area at the front desk, document units in the chart, and tell the patient her unit count at the end of the visit. She gets the simple number when she is deciding and the verifiable number when she is leaving. That single habit removes most of the objection to flat pricing.

How manufacturer loyalty programs interact with each model

The major manufacturers run patient facing loyalty programs, Allē for the AbbVie portfolio, ASPIRE for Galderma, Xperience for Merz and Evolus Rewards for Jeuveau. They generally reward the patient at the point of treatment and they generally require you to register the treatment in the program.

Two things matter for pricing. First, a patient sitting on program points expects to apply them to a total, and a per area total is easier to apply them against cleanly than a unit count that changes at the chair. Second, when a promotion or rebate is tied to product actually used, per unit documentation is what substantiates it. Whichever model you post to the public, your internal record still has to carry the product name, the lot number, the units drawn and the units injected. That record is doing double duty as your rebate substantiation and your adverse event traceability.

See how InjectConsent handles this for medical aesthetics and injectables

Switching models without alienating your existing book

The failure mode is a repeat patient discovering at checkout that the treatment she has had eleven times now costs $80 more and nobody told her. Sequence it instead.

1. Pull ninety days of treatment records and calculate your true average units per area, per injector. Not your intended dose. Your actual dose.
2. Set the flat price off the seventy fifth percentile dose, not the mean, so the common heavy case is still profitable.
3. Write the area definitions down and make every injector sign off that they agree what the boundaries are.
4. Set an effective date at least thirty days out and email existing patients before you change the website.
5. Honor the old model for anyone already booked past the effective date. It costs little and it buys goodwill you will need.
6. Audit at sixty days. Compare realized revenue per vial before and after. If it fell, your percentile was wrong, not the model.

A worked comparison on the same treatment plan

Take one patient, glabella and crow's feet, treated three times a year. Assume a waste adjusted product cost of $6.22 per unit, a per unit price of $13, and flat prices of $325 for glabella and $275 for crow's feet. All of these are assumptions for illustration. Substitute your own.

Scenario	Units	Per unit revenue	Per area revenue	Product cost	Margin difference
Light doser	20 glabella, 16 crow's feet	$468	$600	$224	Per area better by $132
Average doser	24 glabella, 22 crow's feet	$598	$600	$286	Effectively even
Heavy doser	30 glabella, 28 crow's feet	$754	$600	$361	Per unit better by $154

The pattern is the whole answer. Per area wins on light dosers, per unit wins on heavy ones, and the crossover sits near your average. So the model you should pick is determined by the shape of your book, not by preference. If your records show most patients below your average dose, flat pricing is a raise. If they cluster above it, flat pricing is a discount you did not intend to give.

Notice that you cannot run this table without accurate per treatment unit counts. That is the real prerequisite, and it is where most clinics stall.

Where to start this week

Do not change your price list first. Change your record first. For thirty days, capture on every neuromodulator treatment the product name, the lot number, the units drawn, the units injected per area and the units discarded. Then run the table above against your own data and the model will select itself.

That capture is exactly what InjectConsent is built to make routine: signed consent, product and lot number, mapped injection sites and unit counts recorded in the same two minutes as the treatment, with a two week touch up recall attached. Once the units are in the record reliably, pricing stops being a debate and becomes arithmetic you can check every quarter.